AHA Scientific Sessions 2026 Abstract · Nov 2, 2026
Renal Arterial Flow as a Marker of SGLT2 Inhibitors Benefit in Heart Failure
By Salomon P
Background: Renal dysfunction in heart failure (HF) is primarily driven by venous congestion and microvascular impairment rather than reduced cardiac output alone. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) improve HF outcomes, but their effects on renal arterial hemodynamics remain incompletely defined. Objectives: To assess changes in renal arterial flow following SGLT2i initiation and their association with cardiac function and NT-proBNP. Methods: In this single-center observational study, consecutive HF patients initiated on dapagliflozin underwent renal Doppler ultrasound and comprehensive transthoracic echocardiography at baseline and follow-up (~3 months). Renal interlobar artery parameters included pulsatility index (PI), resistive index (RI), and early systolic velocity (ESV/ESP). Echocardiographic measures included LVEF, global longitudinal strain (GLS), E/e′, and global work efficiency (GWE). Laboratory assessments included NT-proBNP, cystatin C, albumin-to-creatinine ratio (ACR), serum creatinine, and eGFR. Changes were analyzed using paired tests, Spearman correlations, and multivariable regression. Results: Among 63 HF patients (age 68±9 years), dapagliflozin was associated with reduced blood pressure without heart rate change. Echocardiography showed improved LVEF and GLS, and reduced E/e′, indicating lower filling pressures. Renal Doppler revealed increases in PI, RI, and ESV/ESP, with no change in acceleration time or aortic flow. NT-proBNP decreased significantly, alongside reductions in albuminuria and cystatin C, while creatinine remained stable. The strongest association was a negative correlation between ΔPI and ΔNT-proBNP (ρ = -0.51; p<0.001). In multivariable analysis, independent predictors of NT-proBNP reduction included ΔE/e′, ΔGLS, ΔPI, and ΔESV/ESP. Conclusions: Dapagliflozin induces early improvement in cardiac hemodynamics and distinct renal arterial flow remodeling. Increased renal pulsatility strongly correlates with NT-proBNP reduction and may serve as a simple, noninvasive marker of effective cardiorenal unloading in HF.